Comparative pharmacodynamic and pharmacokinetic study of MIDD0301 and its (S) enantiomer.
M S Rashid Roni, Nicolas M Zahn, Gene T Yocum, Daniel A Webb, Md Yeunus Mian, Michelle J Meyer, Anika S Tylek, James M Cook, Charles W Emala, Douglas C Stafford and 1 more
Article in Drug development research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 3 institutions in 1 country.
M S Rashid RoniDepartment of Chemistry and Biochemistry, and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.ORCID 0000-0002-3105-0540
Nicolas M ZahnDepartment of Chemistry and Biochemistry, and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.ORCID 0000-0002-2984-6101
Gene T YocumDepartment of Anesthesiology, Columbia University, New York, New York, USA.
Daniel A WebbDepartment of Chemistry and Biochemistry, and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.ORCID 0000-0002-8475-631X
Md Yeunus MianDepartment of Chemistry and Biochemistry, and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Michelle J MeyerDepartment of Chemistry and Biochemistry, and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Anika S TylekDepartment of Chemistry and Biochemistry, and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
James M CookDepartment of Chemistry and Biochemistry, and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Charles W EmalaDepartment of Anesthesiology, Columbia University, New York, New York, USA.
Douglas C StaffordPantherics Incorporated, La Jolla, California, USA.
Leggy A ArnoldDepartment of Chemistry and Biochemistry, and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.ORCID 0000-0003-1411-1572
University of Wisconsin–Milwaukee · USColumbia University · USPanthera Corporation · US
Funding
Anesthetics' Effects on Physiological Responses Modulated by Peripheral GABAA ReceptorsR35GM140880 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI EMALA, CHARLES W · 2021 to 2025
$2.0M
Development of new drugs for asthma by targeting GABA(A) receptors in the lungR01HL118561 · NHLBI · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2014 to 2017
$2.0M
GABAA Receptor-Mediated Modulation of Lung InflammationK08HL140102 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI YOCUM, GENE THOMAS · 2018 to 2022
$831k
Development of microencapsulated PI301 targeting lung GABAergic signalingR43HL162474 · NHLBI · PANTHERICS INCORPORATED · PI STAFFORD, DOUGLAS C. · 2022 to 2022
$256k
A novel asthma drug candidate targeting the GABAergic system in lung inflammationR41HL147658 · NHLBI · PANTHERICS INCORPORATED · PI ARNOLD, ALEXANDER · 2019 to 2019
MIDD0301 is being developed as an oral drug to relax airway smooth muscle (ASM) and reduce lung inflammation in asthma. We report a comparative study of MIDD0301 and its S isomer (MIDD0301S), and found that the compounds have equivalent affinity for γ-aminobutyric acid type A receptor (GABA
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Comparative pharmacodynamic and pharmacokinetic study of MIDD0301 and its (S) enantiomer. · full record | OpenQuestion